Red Acre Investments
Contributor since: 2012
Company: Red Acre Investments
Threshold Pharmaceuticals Raises Cash - An Inside Look At The Deal
Pfizer Starts New Remoxy Trial - Outlook Bullish For Durect And Pain Therapeutics
Spectrum Acquires Talon - A Takeunder Case Study
Vivus Management Moves Signal Desperation
Celsion Dilutes By Fifty Percent
Synergy Pharmaceuticals Stock Undervalued Ahead Of 3 Major Events
The Questcor Bear Raid - An Analysis
Arena Pharmaceuticals APD811 Pipeline Advancement The First Of Several Upcoming Catalysts
Amarin NCE Decision Delayed Again: What The 8-K Really Tells Us
Savient: The Tang Rally Is Over - What's Next
Acadia Pharmaceuticals - Breaking Out For A Second Leg Up
Amarin: A Good Entry Point Ahead Of Major News Next Month
Orexigen Starts Its Road Show - What The Slides Tell Us
Vivus Launches Qsymia - What To Look For Now
Amarin Confirms NCE Delay - What To Look For Now
Acadia Pharmaceuticals Poised For 100% Gain By December
Why Vascepa's NCE Status Might Still Be Unresolved This Month
Vivus' 60 Critical Minutes That Could Double Qsymia's Addressable Market
Derivative Trades On FDA Approval Events
Amarin's Fast Approaching NCE Decision - Does It Even Matter?
Arena's Big Move: What's Behind It?
Amarin Buyout Rumors Gaining Traction?
Knight Capital's Rescue Deal - A Lesson For Biotech Investors
Can Knight Capital Find A White Knight?
On Safety, Vivus Vs. Arena
Don't Let This Biotech Dig Its Talons Into Your Portfolio
Arena Transfers BELVIQ To Eisai - What It Means
Obesity, Heart Disease And Diabetes - A Biotech Triumvirate To Profit From Healthcare Mega-Trends In The Medium Term
Arena Pharmaceuticals Files A Prospectus Supplement - Should Investors Be Concerned?
Obesity Drug Approvals - A Hidden Winner In Supernus